Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma
Aged
Biomarkers, Tumor
Carcinoma, Ductal, Breast
/ diagnosis
Carcinoma, Intraductal, Noninfiltrating
/ diagnosis
Clinical Trials as Topic
Female
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Middle Aged
Neoplasm Grading
Neoplasm Staging
Prognosis
Receptors, Estrogen
/ genetics
Receptors, Progesterone
/ genetics
Recurrence
United Kingdom
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 05 2021
15 05 2021
Historique:
received:
29
11
2020
revised:
25
01
2021
accepted:
05
03
2021
pubmed:
18
3
2021
medline:
17
3
2022
entrez:
17
3
2021
Statut:
ppublish
Résumé
The prognostic value of estrogen receptor (ER)/progesterone receptor (PgR) expression in ductal carcinoma Formalin-fixed paraffin embedded tissues were collected from UK/ANZ DCIS trial participants ( ER expression was multi-clonal in 11% (39/356) of ER-positive (70.6%, 356/504) patients. Ipsilateral breast event (IBE) risk was similarly higher in ER-multi-clonal and ER-negative DCIS as compared with DCIS with uni-clonal ER expression. ER-negative DCIS (clonal) had a higher risk of ER expression is a strong predictor of ipsilateral recurrence risk in DCIS. ER-positive DCIS with distinct ER-negative clones has a recurrence risk similar to ER-negative DCIS. ER should be routinely assessed in DCIS, and ER scoring should take clonality of expression into account.
Identifiants
pubmed: 33727261
pii: 1078-0432.CCR-20-4635
doi: 10.1158/1078-0432.CCR-20-4635
pmc: PMC7611296
mid: EMS128742
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Estrogen
0
Receptors, Progesterone
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2861-2867Subventions
Organisme : Cancer Research UK
ID : A12061
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A16891
Pays : United Kingdom
Informations de copyright
©2021 American Association for Cancer Research.
Références
Breast J. 2008 Jan-Feb;14(1):33-8
pubmed: 18186863
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Breast Cancer Res Treat. 2011 May;127(1):1-14
pubmed: 21327465
Eur J Cancer. 2001 Aug;37(12):1514-22
pubmed: 11506959
Breast Cancer Res Treat. 2012 Jun;133(3):1131-41
pubmed: 22392043
J Natl Cancer Inst. 2010 May 5;102(9):627-37
pubmed: 20427430
Steroids. 2002 Aug;67(9):799-813
pubmed: 12123792
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
Eur J Cancer Prev. 2016 Jan;25(1):19-28
pubmed: 25714649
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251
Mod Pathol. 1998 Feb;11(2):155-68
pubmed: 9504686
Cancer Res. 2009 Jun 1;69(11):4894-903
pubmed: 19487300
Ann Oncol. 2015 Apr;26(4):682-687
pubmed: 25600567
Eur J Cancer. 2018 Sep;101:210-219
pubmed: 30092498
J Clin Oncol. 2012 Apr 20;30(12):1268-73
pubmed: 22393101
Eur J Surg Oncol. 2004 Apr;30(3):243-7
pubmed: 15028303
Breast J. 2015 Mar-Apr;21(2):127-32
pubmed: 25600630
Exp Mol Pathol. 2001 Jun;70(3):303-16
pubmed: 11418009
J Clin Pathol. 1995 Sep;48(9):876-8
pubmed: 7490328
Br J Cancer. 2010 Jun 29;103(1):94-100
pubmed: 20517310
Lancet Oncol. 2011 Jan;12(1):21-9
pubmed: 21145284
Br J Cancer. 2005 Aug 22;93(4):387-91
pubmed: 16106245
J Clin Oncol. 2015 Nov 20;33(33):3938-44
pubmed: 26371148
Eur J Cancer. 2003 Mar;39(5):622-30
pubmed: 12628841
Science. 2014 Oct 10;346(6206):251-6
pubmed: 25301630